MESO   $10.2  -1.16% Market Open

Mesoblast Ltd
Last Events:

2023-08-09 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: entry into the oversold zone.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-06 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Trend Power changed from medium strength to .

2023-08-03 Signal in Stochastic changed from bearish recovery to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-08-02 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-02 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.


Current temperature: 6.42
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 14.50
Mean unverified/preliminary 14.50 / 14.50
Target Price Low / High 11.00 / 18.00
Median / STD DEV 14.50 / 4.95
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy None
ma50 None None None
ma100 Sell Sell None
Candlestick PatternNov. 14, 2024 Bearish Belt Hold - is a candlestick that has a long black body and small shadows. It opens on the high of the day. It occurs in a uptrend. Considered to be a bearish reversal pattern.
ISIN US5907174016
ceo Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Website https://www.mesoblast.com
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.